Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AD-102 (Raloxifene/Cholecalciferol) in Healthy Male Subjects
NCT03824171Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Feb 2019
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of raloxifene and vitamin d in osteoporosis (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Peak Plasma Concentration and Area under the curve in time plot. Started Feb 2019; status: completed.
02
Drugs
raloxifenevitamin d
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03824171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824171.